asco.org7d
Talazoparib and Enzalutamide Combination Improves Survival in Some Patients With Prostate Cancer
“The TALAPRO-2 study showed a significant improvement in overall survival in men with mCRPC treated with the combination of talazoparib and enzalutamide whether they had HRR gene alterations. In this ...
asco.org9d
Additional Noteworthy Studies to be Presented During 2025 ASCO Genitourinary Cancers Symposium
ALEXANDRIA, Va. – Nine studies exploring new approaches for the treatment of genitourinary cancers will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Genitourinary ...
asco.org8d
FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma
The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur: On February 11, 2025, the Food and Drug Administration approved brentuximab vedotin (Adcetris ...
asco.org5d
Phase 1 dose escalation study of MH048, a novel and non-covalent BTK inhibitor in patients with relapsed or refractory B-cell malignancies.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org5d
ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org5d
Comprehensive population-wide detection of Lynch syndrome in Iceland.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org5d
Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC).
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org5d
A phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2 positive advanced gastric cancer (Ni-HIGH study).
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...